Nature Research Round Table: HLA Typing Considerations for Human Pluripotent Stem Cell Banking
Dr. David Turner from the Scottish National Blood Transfusion Service discusses immunological considerations around banking of human pluripotent stem cell (hPSC) lines for use in clinical trials. Dr. Turner’s work at the Histocompatibility and Immunogenetics (H&I) Laboratory involves involves donor-patient HLA-matching for clinical transplants. This presentation and the following Q&A session were moderated by Dr. Joanne Mountford from the University of Glasgow.
This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
Note: Some original data from this presentation has been omitted to abide by copyright rules.
Publish Date:
November 01, 2019
Related Multimedia
-
Nature Research Round Table: Regulations Around Human Induced Pluripotent Stem Cell Registration
Publish Date: November 01, 2019 -
Nature Research Round Table: Standards for Pluripotent Stem Cell Banking
Publish Date: November 01, 2019 -
Nature Research Round Table: Defining and Maintaining Pluripotency & hPSC Line Registration and Banking - Panel Discussion
Publish Date: November 01, 2019
Explore Our Products
-
Serum-free cryopreservation medium for human ES and iPS cells -
Animal component-free suspension culture medium for human ES and iPS cells -
cGMP, stabilized feeder-free maintenance medium for human ES and iPS cells -
cGMP, feeder-free maintenance medium for human ES and iPS cells
